Hartmann’s Solution Compound Sodium Lactate Laboratoire Aguettant

Hartmann’s Solution Compound Sodium Lactate Laboratoire Aguettant is an intravenous electrolyte solution containing potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. It is supplied as a sterile liquid for infusion, without a specified concentration, and is marketed in the European Union as a prescription‑only product. The formulation is designed to replace extracellular fluid, provide essential electrolytes, and assist in correcting metabolic acidosis in clinical practice.

Hartmann’s solution is indicated for several clinical situations that require rapid restoration of intravascular volume and electrolyte balance.

- Fluid resuscitation in patients with hypovolemia due to trauma, surgery, or dehydration. - Electrolyte replacement when sodium, potassium, or calcium deficits are identified. - Correction of metabolic acidosis, particularly in postoperative or critically ill patients. - Maintenance of fluid and electrolyte homeostasis during major operative procedures. - Supportive therapy for patients receiving large volumes of blood products or diuretics. - Prevention of electrolyte shifts during rapid infusion of crystalloids in intensive‑care settings.

Adverse reactions to Hartmann’s solution are generally related to its electrolyte composition and the intravenous route of administration.

Common: - Mild hypernatremia or hyponatremia depending on infusion rate. - Transient potassium or calcium level fluctuations. - Local irritation or pain at the infusion site. - Mild metabolic alkalosis due to lactate metabolism. - Mild increase in serum lactate that resolves after metabolism. - Transient changes in blood pH due to lactate conversion.

Serious: - Severe hyperkalemia leading to cardiac arrhythmia. - Hypercalcemia with potential renal impairment. - Volume overload causing pulmonary edema. - Severe metabolic acidosis if administered inappropriately. - Anaphylactoid reactions such as urticaria, hypotension, or bronchospasm. - Severe electrolyte imbalance leading to neuromuscular dysfunction.

When prescribing Hartmann’s solution, clinicians should evaluate patient-specific factors and monitor parameters to minimize risks associated with electrolyte and volume shifts.

- Assess baseline serum electrolytes, renal function, and acid‑base status before initiation. - Adjust infusion rate in patients with cardiac or renal insufficiency to avoid volume overload. - Use caution in individuals with hyperkalemia, hypercalcemia, or severe metabolic acidosis. - Monitor blood pressure, central venous pressure, and urine output during therapy. - Re‑evaluate electrolyte levels and arterial blood gases regularly, especially after large volumes. - Avoid rapid administration in neonates or patients with compromised vascular integrity.

Hartmann’s solution may interact with other intravenous or oral agents that affect electrolyte balance, cardiac conduction, or fluid status.

Avoid: - Concurrent infusion of high‑dose potassium chloride solutions, which can precipitate severe hyperkalemia. - Administration with calcium‑containing medications when rapid infusion rates are used, increasing risk of calcium overload. - Use with sodium bicarbonate in large volumes, which may exacerbate metabolic alkalosis.

Use with caution: - Loop diuretics, as they can amplify electrolyte shifts; monitor serum levels closely. - ACE inhibitors or ARBs, which may affect potassium handling; adjust monitoring frequency. - Blood products, especially packed red cells, because combined volume may lead to overload.